Estrogen receptor signaling in prostate cancer: Implications for carcinogenesis and tumor progression

被引:142
作者
Bonkhoff, Helmut [1 ]
机构
[1] Pathol Lab, Grossbeerenstr 12, D-12203 Berlin, Germany
关键词
CRPC; ER alpha; ER beta; HGPIN; INTRAEPITHELIAL NEOPLASIA; DIFFERENTIAL EXPRESSION; PREMALIGNANT CHANGES; ANDROGEN RECEPTOR; BETA; TOREMIFENE; ALPHA; MEN; PROGESTERONE; METHYLATION;
D O I
10.1002/pros.23446
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundThe androgen receptor (AR) is the classical target for prostate cancer prevention and treatment, but more recently estrogens and their receptors have also been implicated in prostate cancer development and tumor progression. MethodsRecent experimental and clinical data were reviewed to elucidate pathogenetic mechanisms how estrogens and their receptors may affect prostate carcinogenesis and tumor progression. ResultsThe estrogen receptor beta (ER) is the most prevalent ER in the human prostate, while the estrogen receptor alpha (ER) is restricted to basal cells of the prostatic epithelium and stromal cells. In high grade prostatic intraepithelial neoplasia (HGPIN), the ER is up-regulated and most likely mediates carcinogenic effects of estradiol as demonstrated in animal models. The partial loss of the ER in HGPIN indicates that the ER acts as a tumor suppressor. The tumor promoting function of the TMPRSS2-ERG fusion, a major driver of prostate carcinogenesis, is triggered by the ER and repressed by the ER. The ER is generally retained in hormone naive and metastatic prostate cancer, but is partially lost in castration resistant disease. The progressive emergence of the ER and ER-regulated genes (eg, progesterone receptor (PR), PS2, TMPRSS2-ERG fusion, and NEAT1) during prostate cancer progression and hormone refractory disease suggests that these tumors can bypass the AR by using estrogens and progestins for their growth. In addition, nongenomic estrogen signaling pathways mediated by orphan receptors (eg, GPR30 and ERR) has also been implicated in prostate cancer progression. ConclusionsIncreasing evidences demonstrate that local estrogen signaling mechanisms are required for prostate carcinogenesis and tumor progression. Despite the recent progress in this research topic, the translation of the current information into potential therapeutic applications remains highly challenging and clearly warrants further investigation.
引用
收藏
页码:2 / 10
页数:9
相关论文
共 46 条
[11]  
Chang WY, 1999, PROSTATE, V40, P115
[12]   Inflammation in prostate carcinogenesis [J].
De Marzo, Angelo M. ;
Platz, Elizabeth A. ;
Sutcliffe, Siobhan ;
Xu, Jianfeng ;
Gronberg, Henrik ;
Drake, Charles G. ;
Nakai, Yasutomo ;
Isaacs, William B. ;
Nelson, William G. .
NATURE REVIEWS CANCER, 2007, 7 (04) :256-269
[13]   Insight into the mechanisms of action of estrogen receptor β in the breast, prostate, colon, and CNS [J].
Dey, Prasenjit ;
Barros, Rodrigo P. A. ;
Warner, Margaret ;
Stroem, Anders ;
Gustafsson, Jan-Ake .
JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2013, 51 (03) :T61-T74
[14]   Differential expression of the estrogen receptor beta (ERβ) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma [J].
Fixemer, T ;
Remberger, K ;
Bonkhoff, H .
PROSTATE, 2003, 54 (02) :79-87
[15]   Estrogen related receptor alpha in castration-resistant prostate cancer cells promotes tumor progression in bone [J].
Fradet, Anais ;
Bouchet, Mathilde ;
Delliaux, Carine ;
Gervais, Manon ;
Kan, Casina ;
Benetollo, Claire ;
Pantano, Francesco ;
Vargas, Geoffrey ;
Bouazza, Lamia ;
Croset, Martine ;
Bala, Yohann ;
Leroy, Xavier ;
Rosol, Thomas J. ;
Rieusset, Jennifer ;
Bellahcene, Akeila ;
Castronovo, Vincent ;
Aubin, Jane E. ;
Clezardin, Philippe ;
Duterque-Coquillaud, Martine ;
Bonnelye, Edith .
ONCOTARGET, 2016, 7 (47) :77071-77086
[16]   Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial [J].
Fujimura, Tetsuya ;
Takahashi, Satoru ;
Kume, Haruki ;
Urano, Tomohiko ;
Takayama, Kenichi ;
Yamada, Yuta ;
Suzuki, Motofumi ;
Fukuhara, Hiroshi ;
Nakagawa, Tohru ;
Inoue, Satoshi ;
Homma, Yukio .
BMC CANCER, 2015, 15
[17]   Experience with fulvestrant acetate in castration-resistant prostate cancer patients [J].
Gasent Blesa, J. M. ;
Alberola Candel, V. ;
Giner Marco, V. ;
Giner-Bosch, V. ;
Provencio Pulla, M. ;
Laforga Canales, J. B. .
ANNALS OF ONCOLOGY, 2010, 21 (05) :1131-1132
[18]   Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer [J].
Hedelin, Maria ;
Balter, Katarina Augustsson ;
Chang, Ellen T. ;
Bellocco, Rino ;
Klint, Asa ;
Johansson, Jan-Erik ;
Wiklund, Fredrik ;
Thellenberg-Karlsson, Camilla ;
Adami, Hans-Olov ;
Gronberg, Henrik .
PROSTATE, 2006, 66 (14) :1512-1520
[19]   Estrogens and anti-estrogens: Key mediators of prostate carcinogenesis and new therapeutic candidates [J].
Ho, SM .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2004, 91 (03) :491-503
[20]  
Klein EA, 2002, REV UROL, V4, P18